EGRX vs. RNXT, PMN, AKTX, IXHL, CGTX, LSTA, INKT, KALA, CVM, and MRNS
Should you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include RenovoRx (RNXT), ProMIS Neurosciences (PMN), Akari Therapeutics (AKTX), Incannex Healthcare (IXHL), Cognition Therapeutics (CGTX), Lisata Therapeutics (LSTA), MiNK Therapeutics (INKT), KALA BIO (KALA), CEL-SCI (CVM), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical products" industry.
Eagle Pharmaceuticals vs.
RenovoRx (NASDAQ:RNXT) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Eagle Pharmaceuticals' return on equity of 0.00% beat RenovoRx's return on equity.
In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than RenovoRx. MarketBeat recorded 1 mentions for Eagle Pharmaceuticals and 0 mentions for RenovoRx. Eagle Pharmaceuticals' average media sentiment score of 0.00 beat RenovoRx's score of -1.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the news media.
Eagle Pharmaceuticals has higher revenue and earnings than RenovoRx.
RenovoRx has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.
Eagle Pharmaceuticals received 403 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 67.10% of users gave Eagle Pharmaceuticals an outperform vote while only 47.37% of users gave RenovoRx an outperform vote.
RenovoRx currently has a consensus target price of $6.50, suggesting a potential upside of 333.33%. Given RenovoRx's stronger consensus rating and higher probable upside, research analysts clearly believe RenovoRx is more favorable than Eagle Pharmaceuticals.
Summary
Eagle Pharmaceuticals beats RenovoRx on 10 of the 14 factors compared between the two stocks.
Get Eagle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eagle Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EGRX) was last updated on 1/21/2025 by MarketBeat.com Staff
